Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
AL

NASDAQ · ALXO

ALX Oncology Holdings Inc.

Healthcare · Biotechnology

$1.90

Up+$0.06 (+3.26%)

Updated Sep 11, 2026, 7:25 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
114.42M
P/E ratio
-1.13
Dividend yield
0.00%
52-week range
$1.37 – $2.41
Volume
1.06M
Avg. volume
511.22K

Price performance

ALXO price history

1M range · 20 trading sessions · Daily adjusted prices

ALXO closed at $1.90 after 20 trading sessions, down 2.06% for the selected period.

Last close
$1.90
Period change
-2.06%
Period low
$1.84
Period high
$2.08
Daily close
View OHLC price history
ALXO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$1.85$1.925$1.81$1.901.06M
Sep 9, 2026$1.97$2.02$1.84$1.84770.49K
Sep 8, 2026$1.97$2.02$1.96$2.00425.52K
Sep 4, 2026$2.00$2.03$1.99$2.01301.12K
Sep 3, 2026$2.09$2.09$1.995$2.03603.42K
Sep 2, 2026$1.98$2.09$1.98$2.08855.11K
Sep 1, 2026$1.91$2.00$1.895$1.981.44M
Aug 31, 2026$2.07$2.07$1.895$1.93349.44K
Aug 28, 2026$2.02$2.04$1.98$2.00639.79K
Aug 27, 2026$1.97$2.055$1.965$2.05628.15K
Aug 26, 2026$1.98$2.005$1.95$1.98385.05K
Aug 25, 2026$1.98$2.045$1.98$2.00466.07K
Aug 24, 2026$2.02$2.03$1.95$1.99273.46K
Aug 21, 2026$2.01$2.07$1.98$2.04410.89K
Aug 20, 2026$2.05$2.061$1.97$1.99473.67K
Aug 19, 2026$2.10$2.135$2.025$2.061.22M
Aug 18, 2026$1.95$2.08$1.94$2.08901.32K
Aug 17, 2026$1.93$2.00$1.905$1.97698.7K
Aug 14, 2026$1.95$2.00$1.92$1.96584.16K
Aug 13, 2026$2.01$2.02$1.935$1.94953.66K

Latest ALXO news

The latest Smart Investors Daily articles mentioning ALXO.

Stock researchCompany · Overview

ALXO research

Overview

Company profile and research snapshot.

Company profile

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$21.38
Implied upside
—
Analysts
11
ALXO recent ratings
DateFirmRatingTarget
Mar 19, 2026Wells FargoOverweight—
Mar 10, 2026HC Wainwright & Co.Buy—
Feb 5, 2026Piper SandlerOverweight—
May 21, 2025UBSBuy—
May 9, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

ALX Oncology to Present at Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences. The details of the meetings are as follows: Wells Fargo 21st Annual Healthcare Conference Format: Fireside Chat and One-on-on

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By